Pharmaceuticals company Solara Active Pharma Sciences announced Q3FY25 & 9MFY25 results Revenue: Rs 21,836 lakhs in Q3FY25 (-6% YoY); Rs 68,383 lakhs in 9MFY25 (+5% YoY). EBITDA: Rs 2,625 lakhs in Q3FY25 (-23% YoY); Rs 9,364 lakhs in 9MFY25 (+0.4% YoY). Other Income: Rs 41 lakhs in Q3FY25 (up from Rs -8 lakhs in Q3FY24); Rs 112 lakhs in 9MFY25 (-53% YoY). Profit Before Tax (PBT): Rs 1,235 lakhs in Q3FY25 (-50% YoY); Rs 5,731 lakhs in 9MFY25 (-15% YoY). Profit After Tax (PAT): Rs 932 lakhs in Q3FY25 (-53% YoY); Rs 4,361 lakhs in 9MFY25 (-15% YoY). EBITDA Margin: 12.02% in Q3FY25 (down from 14.71% in Q3FY24); 13.69% in 9MFY25 (down from 14.33% in 9MFY24). PBT Margin: 5.66% in Q3FY25 (down from 10.52% in Q3FY24); 8.38% in 9MFY25 (down from 10.35% in 9MFY24). PAT Margin: 4.27% in Q3FY25 (down from 8.46% in Q3FY24); 6.38% in 9MFY25 (down from 7.93% in 9MFY24). Sunil Chordia Chairman & Managing Director Said: "The performance of the company during this quarter was mixed. Profit before tax was impacted by 50% YoY, as a result of higher interest costs and depreciation as well as a pressure on realisations. Standalone revenues were softer by 0.3% and EBITDA was lower by 23% YoY (consolidated) following a lower coverage of operating costs (fixed costs) for the Chennai plant. India sales by volume increased 10% YoY. There was an increase in sales to new international geographies. The Chennai greenfield plant commenced phased production; assets under use were capitalised from 7th August 2024 and those under installation were reflected in capital work in progress. Chennai trial run losses (Rs 83.9 million) for the period ended 31st December 2024 were capitalised and recognised in CWIP. On the positive side, the company retained its market share across geographies; customer approvals for its new Chennai plant increased, and TPM certification (second stage, Pithampur plant) was received. This indicates a resilience that should translate into improved financials." Result PDF